{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:52:22Z","timestamp":1782849142254,"version":"3.54.5"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Performing germline genetic testing of family members following the identification of an individual with a pathogenic variant in a cancer predisposition gene, a process known as cascade testing, is a critical step in maximizing the preventive benefit of genetic testing for hereditary cancer.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine how often family members undergo cascade testing and to evaluate demographic, socioeconomic, and clinical factors associated with this process.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This retrospective cross-sectional study analyzed demographics, cancer history, genetic test results, and cascade testing data from probands who underwent multigene panel testing between December 2016 and August 2020 at a single diagnostic laboratory. The study cohort included probands found to have a pathogenic or likely pathogenic variant (P\/LPV) in Lynch syndrome (\n MLH1, MSH2, MSH6, PMS2,<\/jats:italic>\n or\n EPCAM<\/jats:italic>\n ) or hereditary breast and ovarian cancer (\n ATM, BRCA1, BRCA2, CHEK2,<\/jats:italic>\n or\n PALB2<\/jats:italic>\n ) genes. Statistical analyses were conducted between June 2023 and March 2025.\n <\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Identification of a P\/LPV in a cancer predisposition gene.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n Variables assessed included proband age, sex, race and ethnicity, socioeconomic status (SES), availability of free testing for family members, cancer history, type of test ordered, and clinician credentials. Differences in cascade testing rates were calculated via 2-sided \u03c7\n 2<\/jats:sup>\n test.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 22\u202f932 probands (18\u202f949 [81.38%] female; mean [SD] age at testing. 51.6 [14.5] years), 5559 (24.24%) had at least 1 family member who underwent cascade testing. Higher rates of cascade testing were seen in individuals aged 40 to 79 years compared with those aged 20 to 39 years (age 40-59 years: 2587 of 10\u202f420 probands [24.83%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001; age 60-79 years: 1960 of 6869 probands [28.53%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001; age \u226580 years: 129 of 462 probands [27.92%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), women (4740 of 18\u202f948 female probands [25.02%] vs 817 of 3963 male probands [20.62%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), non-Hispanic White individuals (3762 of 13\u202f834 probands [27.19%]), those with a personal cancer history vs those without (4712 of 16\u202f674 probands [39.43%] vs 847 of 6261 probands [15.64%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), and those whose care involved genetic counselors vs those whose did not (3614 of 13\u202f847 probands [26.10%] vs 1948 of 9088 probands [21.43%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). People with\n BRCA1<\/jats:italic>\n or\n BRCA2<\/jats:italic>\n variants had higher cascade testing rates compared with those with\n ATM<\/jats:italic>\n ,\n CHEK2<\/jats:italic>\n , or\n PALB2<\/jats:italic>\n variants (2614 of 9699 probands [26.95%] vs 2015 of 8973 probands [22.46%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Several disparities were identified, including lower rates of cascade testing among male probands and probands from racial or ethnic minority groups compared with non-Hispanic White probands (227 of 1406 African American or Black probands [16.15%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001; 175 of 875 Asian probands [20.00%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001; 319 of 1616 Hispanic probands [19.74%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001; 17 of 146 Middle Eastern probands [11.64%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). SES had minimal associations with testing rates, and free family testing was not associated with boosting participation.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this retrospective cross-sectional study, cascade testing was underused, especially among specific demographic groups, with clinical and cultural factors appearing to play a larger role than financial barriers. These findings may guide efforts to address barriers preventing wider uptake of cascade testing and improve cancer prevention efforts, particularly among racial and ethnic minority groups.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.21242","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:08:59Z","timestamp":1782846539000},"page":"e2621242","source":"Crossref","is-referenced-by-count":0,"title":["Differences in Cascade Genetic Testing Among Families With Hereditary Cancer Risk"],"prefix":"10.1001","volume":"9","author":[{"given":"Elia","family":"Namey","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania"},{"name":"University of Virginia School of Medicine, Charlottesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Horton","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Dudley","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassidy","family":"Carraway","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Komala","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Milliard","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Namey","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Karloski","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Brand","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"18","key":"zoi260588r1","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1200\/JCO.20.00299","article-title":"Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology guideline.","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi260588r2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41431-021-01011-8","article-title":"30 Year experience of index case identification and outcomes of cascade testing in high-risk breast and colorectal cancer predisposition genes.","volume":"30","author":"Woodward","year":"2022","journal-title":"Eur J Hum Genet"},{"issue":"19","key":"zoi260588r3","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1002\/cncr.33668","article-title":"Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes.","volume":"127","author":"Makhnoon","year":"2021","journal-title":"Cancer"},{"issue":"9","key":"zoi260588r4","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/gim.2017.231","article-title":"Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers.","volume":"20","author":"Tuffaha","year":"2018","journal-title":"Genet Med"},{"issue":"3","key":"zoi260588r5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/gutjnl-2015-309675","article-title":"Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database.","volume":"66","author":"M\u00f8ller","year":"2017","journal-title":"Gut"},{"issue":"4","key":"zoi260588r6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.5152\/ejbh.2018.4324","article-title":"Risk-reducing options for women with a hereditary breast cancer predisposition.","volume":"14","author":"Jatoi","year":"2018","journal-title":"Eur J Breast Health"},{"issue":"4","key":"zoi260588r7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.amjsurg.2016.06.010","article-title":"Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review.","volume":"212","author":"Ludwig","year":"2016","journal-title":"Am J Surg"},{"issue":"28","key":"zoi260588r8","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1200\/JCO.22.00298","article-title":"The Multicenter Cancer of Pancreas Screening Study: impact on stage and survival.","volume":"40","author":"Dbouk","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi260588r9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0016-5085(00)70168-5","article-title":"Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer.","volume":"118","author":"J\u00e4rvinen","year":"2000","journal-title":"Gastroenterology"},{"issue":"3","key":"zoi260588r10","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1053\/j.gastro.2005.11.032","article-title":"Decrease in mortality in Lynch syndrome families because of surveillance.","volume":"130","author":"de Jong","year":"2006","journal-title":"Gastroenterology"},{"key":"zoi260588r11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.breast.2019.03.011","article-title":"Current knowledge of risk reducing mastectomy: indications, techniques, results, benefits, harms.","volume":"46","author":"Baildam","year":"2019","journal-title":"Breast"},{"issue":"3","key":"zoi260588r12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s12609-020-00364-1","article-title":"Disparities in genetic testing and care among Black women with hereditary breast cancer.","volume":"12","author":"Reid","year":"2020","journal-title":"Curr Breast Cancer Rep"},{"issue":"6","key":"zoi260588r13","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/s41436-018-0349-1","article-title":"Disparities in genetic services utilization in a random sample of young breast cancer survivors.","volume":"21","author":"Nikolaidis","year":"2019","journal-title":"Genet Med"},{"issue":"6","key":"zoi260588r14","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1001\/jamaoncol.2018.0340","article-title":"National distribution of cancer genetic testing in the United States: evidence for a gender disparity in hereditary breast and ovarian cancer.","volume":"4","author":"Childers","year":"2018","journal-title":"JAMA Oncol"},{"key":"zoi260588r15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cancergen.2019.04.063","article-title":"Uptake of genetic testing for germline BRCA1\/2 pathogenic variants in a predominantly Hispanic population.","volume":"235-236","author":"McGuinness","year":"2019","journal-title":"Cancer Genet"},{"issue":"12","key":"zoi260588r16","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.cgh.2018.08.038","article-title":"Low referral rate for genetic testing in racially and ethnically diverse patients despite universal colorectal cancer screening.","volume":"16","author":"Muller","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"zoi260588r17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10689-024-00367-2","article-title":"Cascade genetic testing: an underutilized pathway to equitable cancer care?","volume":"23","author":"Wilke","year":"2024","journal-title":"Fam Cancer"},{"issue":"3","key":"zoi260588r18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10689-011-9454-x","article-title":"Factors associated with an individuals\u2019 decision to withdraw from genetic counseling for BRCA1 and BRCA2 genes mutations: are personality traits involved?","volume":"10","author":"Caruso","year":"2011","journal-title":"Fam Cancer"},{"issue":"6","key":"zoi260588r19","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/1099-1611(200011\/12)9:6<504::AID-PON491>3.0.CO;2-R","article-title":"Uptake of hereditary breast\/ovarian cancer genetic testing in a French national sample of BRCA1 families.","volume":"9","author":"Julian-Reynier","year":"2000","journal-title":"Psychooncology"},{"issue":"2","key":"zoi260588r20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","article-title":"Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome.","volume":"7","author":"Samadder","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi260588r21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ygyno.2019.11.005","article-title":"Low rates of cascade genetic testing among families with hereditary gynecologic cancer: an opportunity to improve cancer prevention.","volume":"156","author":"Griffin","year":"2020","journal-title":"Gynecol Oncol"},{"key":"zoi260588r22","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.867226","article-title":"The impact of proband indication for genetic testing on the uptake of cascade testing among relatives.","volume":"13","author":"Schmidlen","year":"2022","journal-title":"Front Genet"},{"issue":"2","key":"zoi260588r26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10689-022-00316-x","article-title":"Barriers to completion of cascade genetic testing: how can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome?","volume":"22","author":"Kahn","year":"2023","journal-title":"Fam Cancer"},{"issue":"12","key":"zoi260588r27","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41431-020-00725-5","article-title":"Barriers and facilitators for cascade testing in genetic conditions: a systematic review.","volume":"28","author":"Srinivasan","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"zoi260588r28","doi-asserted-by":"crossref","DOI":"10.3389\/fdgth.2022.961128","article-title":"Barriers, interventions, and recommendations: improving the genetic testing landscape.","volume":"4","author":"Dusic","year":"2022","journal-title":"Front Digit Health"},{"issue":"7","key":"zoi260588r30","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/cncr.25589","article-title":"Socioeconomic status and survival after an invasive breast cancer diagnosis.","volume":"117","author":"Sprague","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"zoi260588r31","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/1475-6773.12229","article-title":"Evaluating area-based socioeconomic status indicators for monitoring disparities within health care systems: results from a primary care network.","volume":"50","author":"Berkowitz","year":"2015","journal-title":"Health Serv Res"},{"issue":"1","key":"zoi260588r32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11606-020-06064-x","article-title":"Racial and ethnic disparities in genetic testing at a hereditary breast and ovarian cancer center.","volume":"36","author":"Chapman-Davis","year":"2021","journal-title":"J Gen Intern Med"},{"issue":"1","key":"zoi260588r33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10897-008-9183-y","article-title":"The impact of social roles on the experience of men in BRCA1\/2 families: implications for counseling.","volume":"18","author":"Daly","year":"2009","journal-title":"J Genet Couns"},{"issue":"3","key":"zoi260588r34","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s11764-023-01367-4","article-title":"Screening practices of cancer survivors and individuals whose family or friends had a cancer diagnoses-a nationally representative cross-sectional survey in Japan (INFORM Study 2020).","volume":"17","author":"Akiyama","year":"2023","journal-title":"J Cancer Surviv"},{"issue":"4","key":"zoi260588r36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/GIM.0b013e3182091ba4","article-title":"Underutilization of BRCA1\/2 testing to guide breast cancer treatment: Black and Hispanic women particularly at risk.","volume":"13","author":"Levy","year":"2011","journal-title":"Genet Med"},{"issue":"2","key":"zoi260588r37","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cgh.2020.12.025","article-title":"Racial and ethnic disparities in germline genetic testing of patients with young-onset colorectal cancer.","volume":"20","author":"Dharwadkar","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"22","key":"zoi260588r38","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.2015.66.0019","article-title":"Health Care segregation, physician recommendation, and racial disparities in BRCA1\/2 testing among women with breast cancer.","volume":"34","author":"McCarthy","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi260588r39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1525-1497.2004.40112.x","article-title":"Race and family history assessment for breast cancer.","volume":"20","author":"Murff","year":"2005","journal-title":"J Gen Intern Med"},{"issue":"3","key":"zoi260588r40","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1158\/1055-9965.EPI-09-1138","article-title":"Coherence and completeness of population-based family cancer reports.","volume":"19","author":"Wideroff","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"zoi260588r41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cancergen.2017.09.003","article-title":"Clinical testing with a panel of 25 genes associated with increased cancer risk results in a significant increase in clinically significant findings across a broad range of cancer histories.","volume":"218-219","author":"Rosenthal","year":"2017","journal-title":"Cancer Genet"},{"issue":"4","key":"zoi260588r42","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jmoldx.2019.03.001","article-title":"Multi-gene panel testing of 23,179 individuals for hereditary cancer risk identifies pathogenic variant carriers missed by current genetic testing guidelines.","volume":"21","author":"Neben","year":"2019","journal-title":"J Mol Diagn"},{"issue":"14","key":"zoi260588r43","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1002\/cncr.32077","article-title":"Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma.","volume":"125","author":"Peters","year":"2019","journal-title":"Cancer"},{"key":"zoi260588r29","volume-title":"Creation of New Race-Ethnicity Codes and Socioeconomic Status (SES) Indicators for Medicare Beneficiaries","author":"Bonito","year":"2008"},{"key":"zoi260588r23","unstructured":"Cubit Planning. Income by zip code. Accessed June 30, 2022. https:\/\/www.incomebyzipcode.com\/"},{"key":"zoi260588r24","unstructured":"Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project. Accessed June 30, 2022. https:\/\/www.ahrq.gov\/data\/hcup\/index.html"},{"key":"zoi260588r25","unstructured":"National Comprehensive Cancer Network. Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic: version 3.2026. Accessed May 27, 2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=2&id=1545"},{"key":"zoi260588r35","unstructured":"Centers for Disease Control and Prevention. Prevalence and correlates of family cancer history knowledge and communication among US adults. Accessed July 30, 2024. https:\/\/www.cdc.gov\/pcd\/issues\/2020\/20_0257.htm"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2850959\/namey_2026_oi_260588_1782829144.89764.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:09:10Z","timestamp":1782846550000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2850959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.21242","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}